Oxford University on Saturday, 13th Sep. 2020 announced resuming coronavirus vaccine trials, the study which was suspended following a reported side-effect in a UK patient. Oxford University, developing this vaccine with pharmaceutical company AstraZeneca confirmed the restart across all of its UK clinical trial sites after regulators gave the go-ahead following the pause on Sunday, 6th Sep. 2020.
“The independent review process has concluded and following the recommendations of both the independent safety review committee and the UK regulator, the MHRA, the trials will recommence in the UK,” it said.
With around 18,000 people received it’s vaccine so far and around 30,000 volunteers being recruited in the US, their vaccine stands as a strongest contenders among the dozens of Covid-19 vaccines in various stages of testing around the world. The restart was also welcomed by British health secretary Matt Hancock, stating in a tweet that it was “good news for everyone” and that the trial is “back up and running”. The university said in large trials such as this “it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety”.
